Arcus Biosciences, Inc.
NEWS
This year – 2021 – will be a transformational year, Rosen predicted, citing three important milestones.
Shares of Arcus Biosciences dipped sharply in post-market trading Monday after it was learned that the company’s chief medical officer was departing for a role at Gilead Sciences.
The Biotech Bay region is home to 3,418 life sciences companies and 96,574 employees making an average of $148,285. Here’s a look at a few of the bay area biotech companies hiring now.
The first interim analysis of a three-arm Phase II ARC-7 trial shows Arcus Biosciences’ anti-TIGIT immunotherapy combination features “encouraging clinical activity” as an initial therapy for patients with metastatic non-small cell lung cancer (NSCLC).
With the 2021 American Society of Clinical Oncology Annual Meeting now in high gear, there is plenty of news. Here’s a look at just some of the most recent stories.
The year is starting to pick up in terms of clinical trial announcements. Here’s a look at last week’s news.
Arcus will pair its investigational anti-TIGIT antibody domvanalimab (AB154) with AstraZeneca’s Imfinzi (durvalumab), a checkpoint inhibitor, in a Phase III study with patients who have unresectable Stage III NSCLC.
Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.
Gilead Sciences and Arcus Biosciences signed a 10-year partnership deal to co-develop and co-commercialize a number of Arcus’s pipeline products.
JOBS
IN THE PRESS